Genomic Markers in Prostate Cancer Decision Making.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2017.10.036PMID 29129398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost‐effectiveness of a new urinary biomarker‐based risk score compared to standard of care in prostate cancer diagnostics – a decision analytical model

  2017influential reference
• Cost‐effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer

  2017cited by this paper
• Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

  2017cited by this paper
• Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.

  2017influential reference
• Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

  2017cited by this paper
• Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.

  2017cited by this paper
• Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.

  2017cited by this paper
• DNA Repair in Prostate Cancer: Biology and Clinical Implications.

  2017cited by this paper
• Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

  2017cited by this paper
• Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

  2017influential reference
• Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO‐IMPACT study

  2017cited by this paper
• The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies.

  2017cited by this paper
• Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

  2016cited by this paper
• Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.

  2016cited by this paper
• Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

  2016cited by this paper
• Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

  2016cited by this paper
• Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

  2016cited by this paper
• Prostate Cancer, Version 1.2016.

  2016influential reference
• NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

  2016influential reference
• Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

  2016cited by this paper
• Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer

  2016cited by this paper
• Risk score predicts high‐grade prostate cancer in DNA‐methylation positive, histopathologically negative biopsies

  2016cited by this paper
• A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

  2016cited by this paper
• Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer.

  2016influential reference
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration‑Resistant Prostate Cancer

  2016cited by this paper
• Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.

  2016cited by this paper
• Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

  2015influential reference
• Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

  2015influential reference
• A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

  2015influential reference
• Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

  2015influential reference
• Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

  2015cited by this paper
• Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci

  2015influential reference
• A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result

  2015cited by this paper
• The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

  2015cited by this paper
• The genetic epidemiology of prostate cancer and its clinical implications

  2014cited by this paper
• Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

  2014cited by this paper
• A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

  2014cited by this paper
• Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

  2014cited by this paper
• Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

  2014cited by this paper
• A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

  2014influential reference
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

  2014cited by this paper
• Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014influential reference
• Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.

  2013influential reference
• Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies

  2013influential reference
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013influential reference
• Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

  2013cited by this paper
• Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

  2013cited by this paper
• Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

  2013influential reference
• Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

  2013influential reference
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy

  2013cited by this paper
• Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

  2013cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

  2012cited by this paper
• Germline mutations in HOXB13 and prostate-cancer risk.

  2012cited by this paper
• Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

  2012cited by this paper
• Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

  2011cited by this paper
• Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

  2011cited by this paper
• Genomewide association studies and assessment of the risk of disease.

  2010cited by this paper
• Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

  2009cited by this paper
• Cumulative association of five genetic variants with prostate cancer.

  2008cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper

• Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort.

  2026cites this paper
• From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.

  2026cites this paper
• A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection

  2025cites this paper
• New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management

  2025cites this paper
• Discovery and validation of RAB3B as a diagnostic biomarker for prostate cancer with serum PSA below 10 ng/mL based on a multi-omics study

  2025cites this paper
• Unveiling prognostic biomarkers and immunotherapeutic insights in prostate cancer through multi-omics and machine learning

  2025cites this paper
• An EcDNA gene-based risk model and functional verification of a key ec-lncRNA AC016394.2 for prostate cancer

  2025cites this paper
• EPHB1 Protein Promoted the Progression of Prostate Adenocarcinoma Through Phosphorylating GSK3B and Activating EPHB1-GSK3B-SMAD3 Pathway

  2025cites this paper
• Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review

  2025cites this paper
• Establishing Clinically Significant Prostate Cancer Diagnosis Models Based on Serum Methylation Levels of Four Genes

  2025cites this paper
• Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study

  2025cites this paper
• The potential of ciliary neurotrophic factor receptor as a biomarker for urine-based noninvasive diagnosis of prostate cancer.

  2025cites this paper
• Association between neutrophil percentage-to-albumin ratio and prostate cancer: A cross-sectional study.

  2025cites this paper
• The role of urine derived exosome metalloproteinases as biomarkers for prostate cancer detection may be confounded by non-malignant prostatic inflammation

  2025cites this paper
• Precision Medicine in Prostate Cancer: The Role of Molecular Diagnostics and Targeted Therapies

  2025cites this paper
• Machine learning based androgen receptor regulatory gene-related random forest survival model for precise treatment decision in prostate cancer

  2024cites this paper
• Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review.

  2024cites this paper
• Defining the genetic profile of prostate cancer.

  2024cites this paper
• Clinical implications of AGR2 in primary prostate cancer: Results from a large‐scale study

  2024cites this paper
• Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting.

  2024cites this paper
• Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer

  2024cites this paper
• The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer.

  2024cites this paper
• Individual and Socioeconomic Affecting Factors for Prostate Cancer Screening Behavior

  2024cites this paper
• Exosomes in cancer diagnosis based on the Latest Evidence: Where are We?

  2024cites this paper
• Evidence of the Link between Stroma Remodeling and Prostate Cancer Prognosis

  2024cites this paper
• Prostate tumor markers: diagnosis, prognosis and management

  2024cites this paper
• Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis

  2024cites this paper
• Clinico-Pathological Factors and AR-LBD Mutations in Early and Late Castration-Resistant Prostate Cancer

  2024cites this paper
• Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures

  2023cites this paper
• Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer

  2023cites this paper
• The Bone Microenvironment Soil in Prostate Cancer Metastasis: An miRNA Approach

  2023cites this paper
• Coordinating single‐cell and bulk RNA‐seq in deciphering the intratumoral immune landscape and prognostic stratification of prostate cancer patients

  2023cites this paper
• Expression of nectin-4 in prostate cancer

  2023cites this paper
• Recent advances and future perspectives in the therapeutics of prostate cancer

  2023cites this paper
• EARLY DETECTION OF PROSTATE CANCER: AUA/SUO GUIDELINE

  2023cites this paper
• Prostate‐derived circulating microRNAs add prognostic value to prostate cancer risk calculators

  2023cites this paper
• Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing

  2023cites this paper
• Transcriptome-Wide Association Analysis Identifies Novel Candidate Susceptibility Genes for Prostate-Specific Antigen Levels in Men Without Prostate Cancer

  2023cites this paper
• Molecular Anatomy of Prostate Cancer and Its Implications in Active Surveillance and Early Intervention Strategies

  2023cites this paper
• The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center

  2023cites this paper
• Uncovering the Secrets of Prostate Cancer’s Radiotherapy Resistance: Advances in Mechanism Research

  2023cites this paper
• Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review

  2023cites this paper
• Emerging roles and potential application of PIWI-interacting RNA in urological tumors

  2023cites this paper
• Integrative analysis of ferroptosis regulators for clinical prognosis based on deep learning and potential chemotherapy sensitivity of prostate cancer

  2023cites this paper
• Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?

  2023cites this paper
• Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

  2023cites this paper
• Nurturing the marriages of urinary liquid biopsies and nano‐diagnostics for precision urinalysis of prostate cancer

  2023cites this paper
• Prostate-derived circulating microRNAs add prognostic value to prostate cancer risk calculators

  2023cites this paper
• Value of digital rectal examination in patients with suspected prostate cancer: a prospective cohort analysis study

  2023cites this paper
• The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.

  2023cites this paper
• Diagnostic and Predictive Value of Inflammatory Biomarkers on Prior to Prostate Biopsy

  2023cites this paper
• Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.

  2023cites this paper
• Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer

  2023cites this paper
• 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.

  2023cites this paper
• Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance

  2023cites this paper
• Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence

  2023cites this paper
• Causal isotonic calibration for heterogeneous treatment effects

  2023cites this paper
• Knowledge structure and emerging trends of AR variants in prostate cancer: a bibliometric analysis based on CiteSpace and VOSviewer

  2023cites this paper
• Focal therapy in intermediate- and high-risk prostate cancer

  2023cites this paper
• A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study

  2023cites this paper
• [Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers].

  2022cites this paper
• LncRNA PCGEM1 in Human Cancers: Functions, Mechanisms and Promising Clinical Utility

  2022cites this paper
• Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.

  2022cites this paper
• Prostate cancer biomarkers: a practical review based on different clinical scenarios

  2022cites this paper
• The role of genetic testing in prostate cancer screening, diagnosis, and treatment

  2022cites this paper
• ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER

  2022cites this paper
• Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine

  2022cites this paper
• An MGMT Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients

  2022cites this paper
• Comment on: "Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society".

  2022cites this paper
• Complexities of Prostate Cancer

  2022cites this paper
• The 17-Gene Genomic Prostate Score® Test is Prognostic for Outcomes after Primary External Beam Radiation Therapy in Men with Clinically Localized Prostate Cancer.

  2022cites this paper
• Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques

  2022cites this paper
• The utility of PSA density and free PSA in the prostate biopsy decision pathway in a South African population

  2022cites this paper
• Cell-free DNA in the management of prostate cancer: Current status and future prospective

  2022cites this paper
• PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate

  2022cites this paper
• The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma

  2022cites this paper
• Molecular Pathogenesis of Prostate Cancer

  2022cites this paper
• Diagnostic role of plasma ORM2 in differentiating prostate cancer from benign prostatic hyperplasia

  2022cites this paper
• The Role of Polymorphic Variants of Gene Components of the PTEN/PI3K/AKT Signaling Pathway in the Development of Prostate Cancer

  2022cites this paper
• Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis

  2022cites this paper
• Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States.

  2022cites this paper
• Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care.

  2022cites this paper
• Exosomal CXCL14 Contributes to M2 Macrophage Polarization through NF-κB Signaling in Prostate Cancer

  2022cites this paper
• Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update

  2022cites this paper
• ALDH3A2, ODF2, QSOX2, and MicroRNA-503-5p Expression to Forecast Recurrence in TMPRSS2-ERG-Positive Prostate Cancer

  2022cites this paper
• Prognostic value of PNN in prostate cancer and its correlation with therapeutic significance

  2022cites this paper
• Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies

  2022cites this paper
• Distinct expression signatures of miR-130a, miR-301a, miR-454 in formalin fixed paraffin embedded tissue samples of prostate cancer patients.

  2022cites this paper
• EpCAM as a Novel Biomarker for Survivals in Prostate Cancer Patients

  2022cites this paper
• Identification of microRNA and gene interactions through bioinformatic integrative analysis for revealing candidate signatures in prostate cancer

  2022cites this paper
• SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway

  2022cites this paper
• Learning-Based Cancer Treatment Outcome Prognosis Using Multimodal Biomarkers

  2022cites this paper
• Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy.

  2022cites this paper
• Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study

  2022cites this paper
• The Association of Polymorphisms in Genes Encoding Antioxidant Enzymes GPX1 (rs1050450), SOD2 (rs4880) and Transcriptional Factor Nrf2 (rs6721961) with the Risk and Development of Prostate Cancer

  2022cites this paper
• A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk

  2021cites this paper
• The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource

  2021cites this paper
• The Role and Significance of Bioumoral Markers in Prostate Cancer

  2021cites this paper
• Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer

  2021cites this paper
• Radiogenomics in prostate cancer evaluation

  2021cites this paper